More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.68B
EPS
-2.68
P/E ratio
--
Price to sales
15.06
Dividend yield
--
Beta
0.455518
Previous close
$27.97
Today's open
$27.76
Day's range
$27.59 - $28.61
52 week range
$17.34 - $31.99
CEO
Brian Webster
Employees
443
Headquarters
Kirkland, WA
Exchange
Nasdaq Global Select
Shares outstanding
59561795
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology
KIRKLAND, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced publication of primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, ACE-PAS enrolled 21,612 patients across 35 U.S. states and met both primary safety and effectiveness endpoints. The study demonstrated 100% all-shock conversion success and sustained daily wear, while documenting ventricular arrhythmias early and continuously over subsequent months. The findings strengthen the clinical case for the ASSURE system across WCD indications and underscore the importance of protecting patients throughout periods of elevated arrhythmic risk.
GlobeNewsWire • Nov 16, 2026

Kestra Medical Technologies to Participate in Upcoming Investor Conferences
KIRKLAND, Wash., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to participate in the following upcoming investor conferences:
GlobeNewsWire • Oct 30, 2026

Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies
KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek's list of America's Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating.
GlobeNewsWire • Oct 1, 2026

Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizon
Kestra Medical Technologies is transitioning into a high-growth, high-quality medtech platform with 60% YoY revenue growth and expanding gross margins. KMTS targets mid-70s gross margins within 2–3 years, driven by improved payer mix, scale, and supplier leverage, validating its unit economics story. Despite strong top-line momentum and raised FY27 guidance, profitability remains distant with a $44M net loss and $32M quarterly cash burn.
Seeking Alpha • Sep 16, 2026

Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures falling around 200 points on Tuesday.
Benzinga • Sep 15, 2026

Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
Seeking Alpha • Sep 15, 2026

Kestra Medical Technologies Q1 Earnings Call Highlights
Kestra Medical Technologies NASDAQ: KMTS reported first-quarter fiscal 2027 revenue of $31 million, with President and Chief Executive Officer Brian Webster saying revenue rose 60% from a year earlier and advanced sequentially from the fourth quarter. The company raised its full-year revenue outlook to $141 million from a prior forecast of $137 million, representing expected growth of 48% over fiscal 2026.
MarketBeat • Sep 14, 2026

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.
GlobeNewsWire • Sep 14, 2026

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates
Kestra Medical Technologies, Ltd. (KMTS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61.
Zacks Investment Research • Sep 14, 2026

Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) will release its first earnings report after the closing bell on Monday, Sept.
Benzinga • Sep 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Kestra Medical Technologies Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.